Combinatorial ablation and immunotherapy: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m →‎Mechanism of action: task, replaced: Gastroenterol Res Pract. → Gastroenterol Res Pract using AWB
Citation bot (talk | contribs)
Bots
4,908,245 edits
m Alter: journal. Add: journal, pmc, pmid, pages, issue, volume, author pars. 1-3. Removed parameters. Formatted dashes. You can use this bot yourself. Report bugs here. | User-activated; Category:Pages_with_DOIs_inactive_since_2017.
Line 1: Line 1:
'''Combinatorial ablation and immunotherapy''' is an oncological treatment that combines various tumor-ablation techniques with immunotherapy treatment.<ref>{{Cite journal | author = Dupuy, et al. | title = Thermal ablation of tumours: biological mechanisms and advances in therapy| journal = Nature Reviews Cancer| volume = 14| issue = 3| pages = 199–208| year = 2014| doi = 10.1038/nrc3672| pmid = 24561446| url=http://www.nature.com/nrc/journal/v14/n3/abs/nrc3672.html}}</ref><ref name=hindawi9251375>{{Cite journal | title = Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?| year = 2015| url=https://www.hindawi.com/journals/grp/2016/9251375/}}</ref><ref name="interventionalnews">{{Cite web | title = Immunotherapy could transform systemic power of locoregional IO treatments| year = 2016| url=https://interventionalnews.com/immunotherapy-could-transform-systemic-power-of-locoregional-io-treatments/}}</ref><ref>{{Cite book | title = Cancer Immunology and Immunotherapy| year = 2016| url=https://books.google.com/books?id=XSM545kh36oC&pg=PA218/|page=218| isbn = 9783642141362| author1 = Dranoff| first1 = Glenn}}</ref> Combining ablation therapy of tumors with immunotherapy enhances the immunostimulating response and has synergistic effects for curative metastatic cancer treatment.<ref name=hindawi9251375/><ref name="interventionalnews"/> Various ablative techniques are utilized including [[cryoimmunology|cryoablation]], radiofrequency ablation, laser ablation, [[Photoimmunotherapy|photodynamic ablation]], [[stereotactic radiation therapy]], [[hyperthermia therapy]], [[HIFU]].<ref>{{Cite web | author = Prof. Yona Keisari | title = Development of Cancer Treatments Integrating Radiotherapy or Electrochemical Ablation and Immunotherapy | url=https://en-med.tau.ac.il/research_ablation}}</ref><ref>{{Cite journal | year= 2003 | title = Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma | journal = Cancer science | volume = 94 | issue = 3 | pages = 308–13 | pmid = 12824927 | author1 = Ito | first1 = A | last2 = Tanaka | first2 = K | last3 = Kondo | first3 = K | last4 = Shinkai | first4 = M | last5 = Honda | first5 = H | last6 = Matsumoto | first6 = K | last7 = Saida | first7 = T | last8 = Kobayashi | first8 = T }}</ref><ref>{{Cite journal | author =Xiaoming Yang | year = 2016 | title = Radiofrequency hyperthermia promotes the therapeutic effects on chemotherapeutic-resistant breast cancer when combined with heat shock protein promoter-controlled HSV-TK gene therapy: Toward imaging-guided interventional gene therapy | journal = Oncotarget | doi = 10.18632/oncotarget.11346 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323137/}}</ref><ref>{{Cite journal | year= 2000 | title = Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter | journal = Human Gene Therapy | volume = 11 | issue = 18 | pages = 2453–63 | pmid = 11119417 | author1 = Braiden | first1 = V | last2 = Ohtsuru | first2 = A | last3 = Kawashita | first3 = Y | last4 = Miki | first4 = F | last5 = Sawada | first5 = T | last6 = Ito | first6 = M | last7 = Cao | first7 = Y | last8 = Kaneda | first8 = Y | last9 = Koji | first9 = T | last10 = Yamashita | first10 = S | doi = 10.1089/10430340050207948 }}</ref><ref>{{Cite book | year= 2016 | title = Hyperthermic Oncology from Bench to Bedside | pages = 319 | url=https://link.springer.com/chapter/10.1007%2F978-981-10-0719-4_30| doi = 10.1007/978-981-10-0719-4_30 | chapter = Combination by Hyperthermia and Immunotherapy: DC Therapy and Hyperthermia | last1 = Takeda | first1 = Tsutomu | last2 = Takeda | first2 = Takashi | isbn = 978-981-10-0717-0 }}</ref><ref>{{Cite journal | journal=Austin Oncol Case Rep |year= 2017 | title = A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination | url=http://www.iozk.de/aktuelles/iozk_austin_oncology_case_reports_2017.pdf}}</ref> Thus, combinatorial ablation of tumors and immunotherapy is a way of achieving [[autologous]], [[in-vivo]] tumor [[lysate]] vaccine and treat [[metastatic]] disease.
'''Combinatorial ablation and immunotherapy''' is an oncological treatment that combines various tumor-ablation techniques with immunotherapy treatment.<ref>{{Cite journal | author = Dupuy, et al. | title = Thermal ablation of tumours: biological mechanisms and advances in therapy| journal = Nature Reviews Cancer| volume = 14| issue = 3| pages = 199–208| year = 2014| doi = 10.1038/nrc3672| pmid = 24561446| url=http://www.nature.com/nrc/journal/v14/n3/abs/nrc3672.html}}</ref><ref name=hindawi9251375>{{Cite journal | title = Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?| year = 2015| url=https://www.hindawi.com/journals/grp/2016/9251375/}}</ref><ref name="interventionalnews">{{Cite web | title = Immunotherapy could transform systemic power of locoregional IO treatments| year = 2016| url=https://interventionalnews.com/immunotherapy-could-transform-systemic-power-of-locoregional-io-treatments/}}</ref><ref>{{Cite book | title = Cancer Immunology and Immunotherapy| year = 2016| url=https://books.google.com/books?id=XSM545kh36oC&pg=PA218/|page=218| isbn = 9783642141362| author1 = Dranoff| first1 = Glenn}}</ref> Combining ablation therapy of tumors with immunotherapy enhances the immunostimulating response and has synergistic effects for curative metastatic cancer treatment.<ref name=hindawi9251375/><ref name="interventionalnews"/> Various ablative techniques are utilized including [[cryoimmunology|cryoablation]], radiofrequency ablation, laser ablation, [[Photoimmunotherapy|photodynamic ablation]], [[stereotactic radiation therapy]], [[hyperthermia therapy]], [[HIFU]].<ref>{{Cite web | author = Prof. Yona Keisari | title = Development of Cancer Treatments Integrating Radiotherapy or Electrochemical Ablation and Immunotherapy | url=https://en-med.tau.ac.il/research_ablation}}</ref><ref>{{Cite journal | year= 2003 | title = Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma | journal = Cancer Science | volume = 94 | issue = 3 | pages = 308–13 | pmid = 12824927 | author1 = Ito | first1 = A | last2 = Tanaka | first2 = K | last3 = Kondo | first3 = K | last4 = Shinkai | first4 = M | last5 = Honda | first5 = H | last6 = Matsumoto | first6 = K | last7 = Saida | first7 = T | last8 = Kobayashi | first8 = T }}</ref><ref>{{Cite journal | author =Xiaoming Yang | year = 2016 | title = Radiofrequency hyperthermia promotes the therapeutic effects on chemotherapeutic-resistant breast cancer when combined with heat shock protein promoter-controlled HSV-TK gene therapy: Toward imaging-guided interventional gene therapy | journal = Oncotarget | volume = 7 | issue = 40 | pages = 65042–65051 | doi = 10.18632/oncotarget.11346 | pmid = 27542255 | pmc = 5323137 }}</ref><ref>{{Cite journal | year= 2000 | title = Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter | journal = Human Gene Therapy | volume = 11 | issue = 18 | pages = 2453–63 | pmid = 11119417 | author1 = Braiden | first1 = V | last2 = Ohtsuru | first2 = A | last3 = Kawashita | first3 = Y | last4 = Miki | first4 = F | last5 = Sawada | first5 = T | last6 = Ito | first6 = M | last7 = Cao | first7 = Y | last8 = Kaneda | first8 = Y | last9 = Koji | first9 = T | last10 = Yamashita | first10 = S | doi = 10.1089/10430340050207948 }}</ref><ref>{{Cite book | year= 2016 | title = Hyperthermic Oncology from Bench to Bedside | pages = 319 | doi = 10.1007/978-981-10-0719-4_30 | chapter = Combination by Hyperthermia and Immunotherapy: DC Therapy and Hyperthermia | last1 = Takeda | first1 = Tsutomu | last2 = Takeda | first2 = Takashi | isbn = 978-981-10-0717-0 }}</ref><ref>{{Cite journal | journal=Austin Oncol Case Rep |year= 2017 | title = A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination | url=http://www.iozk.de/aktuelles/iozk_austin_oncology_case_reports_2017.pdf}}</ref> Thus, combinatorial ablation of tumors and immunotherapy is a way of achieving [[autologous]], [[in-vivo]] tumor [[lysate]] vaccine and treat [[metastatic]] disease.


==Mechanism of action==
==Mechanism of action==
Take magnetic hyperthermia for example. By applying magnetic nanoparticle-mediated hyperthermia with a threshold of 43&nbsp;°C in order not to damage surrounding normal tissues, a significant amount of heat-shock proteins (HSP) is expressed within and around the tumor tissues, inducing tumor-specific immune responses. In vivo experiments have indicated that magnetic nanoparticle-mediated hyperthermia can induce the regression of not only a local tumor tissue
Take magnetic hyperthermia for example. By applying magnetic nanoparticle-mediated hyperthermia with a threshold of 43&nbsp;°C in order not to damage surrounding normal tissues, a significant amount of heat-shock proteins (HSP) is expressed within and around the tumor tissues, inducing tumor-specific immune responses. In vivo experiments have indicated that magnetic nanoparticle-mediated hyperthermia can induce the regression of not only a local tumor tissue


exposed to heat, but also distant metastatic tumors unexposed to heat. Partially or entirely ablating primary or secondary metastatic tumors induces necrosis of tumor cells, resulting in the release of antigens and presentation of antigens to the immune system. The released tumor antigens help activate anti-tumor T cells, which can destroy remaining malignant cells in local and distant tumors. Combining [[Cancer immunotherapy|immunotherapy]] (ie: checkpoint inhibitors, [[Chimeric antigen receptor|CAR-T cell therapy]]) and vaccine adjuvants (ie: [[interferon]], [[saponin]]) with ablation synergizes the immune reaction, and can treat metastatic disease with curative intent.<ref name="interventionalnews" /><ref>{{cite journal | year = 2015 |title = Cryo-thermal therapy elicits potent anti-tumor immunity.| url =http://www.nature.com/articles/srep27136}}</ref><ref>Cryosurgery initiates inflammation and leaves tumor-specific antigens intact, which may induce an anti-tumor immune response.{{cite journal | year = 2005 |title = Immunologic response to cryoablation of breast cancer | author = Sabel | pmc=4115762 | pmid=25083502 | doi=10.3978/j.issn.2227-684X.2014.03.04 | volume=3 |issue = 2 | journal=Gland Surg | pages=88–93|doi-broken-date = 2017-05-16 }}</ref><ref>{{cite journal | year = 2005 |title = Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity.| url =http://clincancerres.aacrjournals.org/content/11/13/4955}}</ref><ref>{{cite journal | year = 2016 |title = Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response| journal = Gastroenterol Res Pract | doi=10.1155/2016/9251375 | volume=2016 | pages=1–11|last1 = Mehta|first1 = Amol|last2 = Oklu|first2 = Rahmi|last3 = Sheth|first3 = Rahul A.}}</ref><ref>{{Cite journal | year= 2012 | title = Nanoparticle-mediated hyperthermia in cancer therapy. | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323111/}}</ref>
exposed to heat, but also distant metastatic tumors unexposed to heat. Partially or entirely ablating primary or secondary metastatic tumors induces necrosis of tumor cells, resulting in the release of antigens and presentation of antigens to the immune system. The released tumor antigens help activate anti-tumor T cells, which can destroy remaining malignant cells in local and distant tumors. Combining [[Cancer immunotherapy|immunotherapy]] (ie: checkpoint inhibitors, [[Chimeric antigen receptor|CAR-T cell therapy]]) and vaccine adjuvants (ie: [[interferon]], [[saponin]]) with ablation synergizes the immune reaction, and can treat metastatic disease with curative intent.<ref name="interventionalnews" /><ref>{{cite journal | year = 2015 |title = Cryo-thermal therapy elicits potent anti-tumor immunity.| url =http://www.nature.com/articles/srep27136}}</ref><ref>Cryosurgery initiates inflammation and leaves tumor-specific antigens intact, which may induce an anti-tumor immune response.{{cite journal | year = 2005 |title = Immunologic response to cryoablation of breast cancer | author = Sabel | pmc=4115762 | pmid=25083502 | doi=10.3978/j.issn.2227-684X.2014.03.04 | volume=3 |issue = 2 | journal=Gland Surg | pages=88–93}}</ref><ref>{{cite journal | year = 2005 |title = Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity.| url =http://clincancerres.aacrjournals.org/content/11/13/4955}}</ref><ref>{{cite journal | year = 2016 |title = Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response| journal = Gastroenterol Res Pract | doi=10.1155/2016/9251375 |pmid = 27051417|pmc = 4802022| volume=2016 | pages=1–11|last1 = Mehta|first1 = Amol|last2 = Oklu|first2 = Rahmi|last3 = Sheth|first3 = Rahul A.}}</ref><ref>{{Cite journal | year= 2012 | title = Nanoparticle-mediated hyperthermia in cancer therapy. | journal = Therapeutic Delivery | volume = 2 | issue = 8 | pages = 1001–1014 | pmc = 3323111 | last1 = Chatterjee | first1 = D. K. | last2 = Diagaradjane | first2 = P. | last3 = Krishnan | first3 = S. | pmid = 22506095 }}</ref>


==Ablation therapies==
==Ablation therapies==

Revision as of 20:31, 21 September 2018

Combinatorial ablation and immunotherapy is an oncological treatment that combines various tumor-ablation techniques with immunotherapy treatment.[1][2][3][4] Combining ablation therapy of tumors with immunotherapy enhances the immunostimulating response and has synergistic effects for curative metastatic cancer treatment.[2][3] Various ablative techniques are utilized including cryoablation, radiofrequency ablation, laser ablation, photodynamic ablation, stereotactic radiation therapy, hyperthermia therapy, HIFU.[5][6][7][8][9][10] Thus, combinatorial ablation of tumors and immunotherapy is a way of achieving autologous, in-vivo tumor lysate vaccine and treat metastatic disease.

Mechanism of action

Take magnetic hyperthermia for example. By applying magnetic nanoparticle-mediated hyperthermia with a threshold of 43 °C in order not to damage surrounding normal tissues, a significant amount of heat-shock proteins (HSP) is expressed within and around the tumor tissues, inducing tumor-specific immune responses. In vivo experiments have indicated that magnetic nanoparticle-mediated hyperthermia can induce the regression of not only a local tumor tissue

exposed to heat, but also distant metastatic tumors unexposed to heat. Partially or entirely ablating primary or secondary metastatic tumors induces necrosis of tumor cells, resulting in the release of antigens and presentation of antigens to the immune system. The released tumor antigens help activate anti-tumor T cells, which can destroy remaining malignant cells in local and distant tumors. Combining immunotherapy (ie: checkpoint inhibitors, CAR-T cell therapy) and vaccine adjuvants (ie: interferon, saponin) with ablation synergizes the immune reaction, and can treat metastatic disease with curative intent.[3][11][12][13][14][15]

Ablation therapies

Various local ablation therapies exist to induce necrosis of tumor cells and release tumor antigens for an immunological response, this is combined with immunotherapy:

  • Thermal ablation – local thermal ablation of tumor:
  • Nanotechnology in thermal ablation and immunotherapy
    • Currently nanotechnologies has been continuously developed for cancer immunotherapy for their versatility in integration of therapeutic and diagnostic (or termed 'theranostic') multimodalities. For example, iron oxide nanoparticles can generate heat under alternating magnetic field (100 kHz to 1 MHz); and they can also be utilized as imaging contrast agents for magnetic resonance imaging (MRI) for visualizing and monitoring the generation, distribution and biological activities of iron oxide nanoparticles. Magnetic nanoparticles can be concentrated to the tumor site via externally applied magnetic field, which is also advantageous in minimizing dose-related side effects. Localized heat can also trigger release of certain anti-cancer immuno-therapeutics loading from the nano-scale cargos if the nanomaterials are heat-responsive. From biological aspect, local heating can in addition significantly increase the extravasation of nanoscale drug carriers from tumor vessels, which enhances the performance of anti-cancer drug delivery to target cancers.

See also

References

  1. ^ Dupuy; et al. (2014). "Thermal ablation of tumours: biological mechanisms and advances in therapy". Nature Reviews Cancer. 14 (3): 199–208. doi:10.1038/nrc3672. PMID 24561446. {{cite journal}}: Explicit use of et al. in: |author= (help)
  2. ^ a b "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?". 2015. {{cite journal}}: Cite journal requires |journal= (help)
  3. ^ a b c "Immunotherapy could transform systemic power of locoregional IO treatments". 2016.
  4. ^ Dranoff, Glenn (2016). Cancer Immunology and Immunotherapy. p. 218. ISBN 9783642141362.
  5. ^ Prof. Yona Keisari. "Development of Cancer Treatments Integrating Radiotherapy or Electrochemical Ablation and Immunotherapy".
  6. ^ Ito, A; Tanaka, K; Kondo, K; Shinkai, M; Honda, H; Matsumoto, K; Saida, T; Kobayashi, T (2003). "Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma". Cancer Science. 94 (3): 308–13. PMID 12824927.
  7. ^ Xiaoming Yang (2016). "Radiofrequency hyperthermia promotes the therapeutic effects on chemotherapeutic-resistant breast cancer when combined with heat shock protein promoter-controlled HSV-TK gene therapy: Toward imaging-guided interventional gene therapy". Oncotarget. 7 (40): 65042–65051. doi:10.18632/oncotarget.11346. PMC 5323137. PMID 27542255.
  8. ^ Braiden, V; Ohtsuru, A; Kawashita, Y; Miki, F; Sawada, T; Ito, M; Cao, Y; Kaneda, Y; Koji, T; Yamashita, S (2000). "Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter". Human Gene Therapy. 11 (18): 2453–63. doi:10.1089/10430340050207948. PMID 11119417.
  9. ^ Takeda, Tsutomu; Takeda, Takashi (2016). "Combination by Hyperthermia and Immunotherapy: DC Therapy and Hyperthermia". Hyperthermic Oncology from Bench to Bedside. p. 319. doi:10.1007/978-981-10-0719-4_30. ISBN 978-981-10-0717-0.
  10. ^ "A New Strategy of Cancer Immunotherapy Combining Hyperthermia/Oncolytic Virus Pretreatment with Specific Autologous Anti-Tumor Vaccination" (PDF). Austin Oncol Case Rep. 2017.
  11. ^ "Cryo-thermal therapy elicits potent anti-tumor immunity". 2015. {{cite journal}}: Cite journal requires |journal= (help)
  12. ^ Cryosurgery initiates inflammation and leaves tumor-specific antigens intact, which may induce an anti-tumor immune response.Sabel (2005). "Immunologic response to cryoablation of breast cancer". Gland Surg. 3 (2): 88–93. doi:10.3978/j.issn.2227-684X.2014.03.04. PMC 4115762. PMID 25083502.
  13. ^ "Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity". 2005. {{cite journal}}: Cite journal requires |journal= (help)
  14. ^ Mehta, Amol; Oklu, Rahmi; Sheth, Rahul A. (2016). "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response". Gastroenterol Res Pract. 2016: 1–11. doi:10.1155/2016/9251375. PMC 4802022. PMID 27051417.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  15. ^ Chatterjee, D. K.; Diagaradjane, P.; Krishnan, S. (2012). "Nanoparticle-mediated hyperthermia in cancer therapy". Therapeutic Delivery. 2 (8): 1001–1014. PMC 3323111. PMID 22506095.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Combinatorial_ablation_and_immunotherapy&oldid=860604882"